erlotinib hydrochloride has been researched along with Carcinoma, Epidermoid in 247 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 51 (20.65) | 29.6817 |
| 2010's | 183 (74.09) | 24.3611 |
| 2020's | 13 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, F; Huang, X; Liu, S; Wang, H; Wen, J | 1 |
| Abe, S; Kusaba, Y; Naka, G; Takeda, Y; Tsukada, A | 1 |
| Chang, QZ; Chen, JC; Chiang, CS; Chien, CC; Hsieh, JM; Huang, IH; Ko, JC; Lin, YW; Liu, LL; Mu, BC; Tseng, PY | 1 |
| Chan, CY; Chang, CM; Chen, YH; Hong, SC; Huang, CY; Liao, PC | 1 |
| Dave, H; Hariharan, K; Mehta, T; Omri, A; Sami, A; Shah, J | 1 |
| Buzdin, A; Gaifullin, N; Garazha, A; Kamashev, D; Lebedev, T; Poddubskaya, E; Prassolov, V; Raevskiy, M; Sekacheva, M; Shaban, N; Sorokin, M; Suntsova, M | 1 |
| Edwards, A; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Lal, R; Lee, SM; Lewanski, C; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Guan, R; Hu, D; Jiang, W; Li, K; Li, Y; Liao, D; Liu, L; Mansfield, AS; Wang, J; Xia, C; Xiao, L; Xiong, Y; Yang, H; Yang, N; Zeng, L; Zhang, Y; Zhou, C | 1 |
| Chan, CY; Chang, CM; Chen, YH; Huang, CY; Lin, TY; Sheu, JJ | 1 |
| Baxter, MA; Petty, RD; Spender, LC | 1 |
| Bleilevens, A; Denecke, B; Denzinger, S; Ecke, T; Eltze, E; Eyll, M; Gaisa, NT; Geelvink, M; Gereitzig, M; Grimm, T; Herrmann, E; Horst, D; Knuechel, R; Maurer, A; Maurer, J; Rose, M; Rüchel, N; Toma, M; Vögeli, TA; Waldmann, T; Wenz, M; Wirtz, J | 1 |
| Burandt, E; Coym, A; Hillen, C; Jaeger, A; Kuerti, S; Mathey, S; Mueller, V; Prieske, K; Schmalfeldt, B; Woelber, L | 1 |
| Chatterjee, A; Gowda, H; Jain, AP; Keshava Prasad, TS; Kumar, M; Mathur, PP; Nanjappa, V; Patel, K; Pinto, S; Radhakrishnan, A; Raja, R; Sidransky, D | 1 |
| Argiris, A; Burns, TF; Dacic, S; Farooqui, M; Floros, T; Friedland, DM; Gaither-Davis, A; Gomez-Garcia, J; Gooding, WE; Petro, DP; Rafique, I; Siegfried, JM; Socinski, MA; Stabile, LP; Tarhini, AA; Tran, P; Villaruz, LC | 1 |
| Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD | 1 |
| Ardizzoni, A; Bühnemann, C; Cobo, M; Dupuis, N; Ehrnrooth, E; Felip, E; Gadgeel, S; Georgoulias, V; Göker, E; Goss, G; Guclu, SZ; Isla, D; Krämer, N; Lee, KH; Lu, S; Morabito, A; Solca, F; Soria, JC; Syrigos, K | 1 |
| Cobo, M; Dayen, C; Ehrnrooth, E; Felip, E; Fülöp, A; Gadgeel, SM; Gordon, J; Goss, GD; Gregg, R; Hirsh, V; Palmer, M; Popat, S; Soria, JC; Trigo, JM; Waller, CF; Wang, B | 1 |
| Amanuma, Y; Chiba, T; Ida, T; Kikuchi, O; Matsubara, J; Miyamoto, S; Muto, M; Nakagawa, H; Nakai, Y; Natsuizaka, M; Ohashi, S; Seno, H; Yamada, A; Yoshioka, M | 1 |
| Chen, J; Chen, Q; Liang, C; Liu, Z; Xu, L; Yang, Y; Yang, Z | 1 |
| Celik, B; Demirag, MK; Elmali, M; Gulel, O | 1 |
| Ding, X; Dong, Y; Gu, W; Song, X; Wang, Z; Wu, Y; Zhang, W; Zheng, Y; Zhong, Y | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Bosch-Barrera, J; Guerra Prió, S; Hernández Martínez, A; Izquierdo Font, A; López Brunsó, M; Mas Pueyo, HG; Roa García, D; Sais Girona, E; Toro Blanch, C | 1 |
| Basu, S; Batus, M; Bonomi, P; Borgia, JA; Fhied, CL; Fidler, MJ; Fughhi, I; Pool, M; Roder, J; Sayidine, S | 1 |
| Glisson, BS; Gold, KA; Johnson, FM; Kies, MS; Lee, JJ; William, WN | 1 |
| Chu, YB; Fu, J; He, W; Kuo, D; Wu, B; Ye, M; Zhang, YJ; Zhao, YY; Zhu, J | 1 |
| Ardizzoni, A; Bühnemann, C; Cobo, M; Cseh, A; Ehrnrooth, E; Felip, E; Fülöp, A; Gadgeel, SM; Georgoulias, V; Gibson, N; Göker, E; Goss, GD; Guclu, S; Isla, D; Krämer, N; Lee, KH; Li, W; Lu, S; Min, YJ; Morabito, A; Solca, F; Soria, JC; Syrigos, K | 1 |
| Gandara, DR; Lara, PN; Riess, JW | 1 |
| Hase, T; Hasegawa, Y; Matsui, A; Morise, M; Omote, N; Sato, M; Shimoyama, Y; Suzuki, K; Tanaka, I | 1 |
| Alama, A; Biello, F; Boccardo, S; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Rossi, G; Tagliamento, M | 1 |
| Agarwal, V; Nayar, RC; Rao, V; Subash, A | 1 |
| Cheong, SC; Fadlullah, MZH; Gan, CP; Kelly, GM; Lee, BKB; Lee, HM; Patel, V; Yee, PS; Zainal, NS | 1 |
| Ather, F; Fejzo, MS; Finn, RS; Hamidi, H; Head, C; Kabbinavar, F; Letrent, S; Wong, SG | 1 |
| Amin, AR; Beitler, JJ; Brandes, JC; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, WJ; Khuri, FR; Kono, S; Lewis, M; Moreno-Williams, R; Müller, S; Nannapaneni, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Thomas, SM; Zhang, H | 1 |
| Gaffney, DC; Simpson, F; Soyer, HP | 1 |
| Austin, M; Bauman, JE; Chai, X; Eaton, KD; Futran, N; Hayes, DN; Kurland, BF; Liao, JJ; Martins, RG; Mendez, E; Papagikos, MA; Parvathaneni, U; Raez, LE; Schmidt, R; Sharma, AK; Wallace, SG; Wang, DX; Yunus, F | 1 |
| Atagi, S; Fukuoka, M; Imai, M; Katakami, N; Kudoh, S; Matsui, S; Ogiwara, A; Ueda, M; Yoshioka, H | 1 |
| Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Hsu, JH; Li, MF; Shiau, EL; Wu, MT | 1 |
| Kieszko, R; Kowalski, DM; Krawczyk, KW; Krawczyk, P; Krzakowski, M; Milanowski, J; Mlak, R; Rolski, A; Szczyrek, M; Szudy, A; Winiarczyk, K | 1 |
| Aydiner, A; Seyidova, A; Yildiz, I | 1 |
| Chhatrala, R; Iyer, R; Khushalani, N; Levea, C; Malhotra, U; Robins, M; Shefter, T; Tan, W; Yang, G | 1 |
| Chalasani, P; Clausen, C; Dhiwakar, M; Kalapurakal, S; Malone, J; Rao, K; Robbins, KT; Robinson, K; Ronen, O; Shevlin, B | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Havel, L; Hrnciarik, M; Krejci, J; Minarik, M; Pesek, M; Salajka, F | 1 |
| Case, AJ; Domann, FE; Fletcher, EV; Love-Homan, L; Miller, FJ; Raeburn, A; Schickling, BM; Simons, AL; Sobhakumari, A | 1 |
| Basu, D; Bewley, AF; Diehl, JA; Facompre, ND; Gimotty, PA; Herlyn, M; Montone, KT; Nakagawa, H; Rasanen, K; Rustgi, AK; Sperry, SM; Weinstein, GS | 1 |
| Falchook, GS; Fok, JY; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, RG | 1 |
| Biddinger, P; Dillard, T; Hao, Z; Patel, V | 1 |
| Stinchcombe, TE | 1 |
| Fishbein, M; Marchevsky, A; Reckamp, KL; Saldivar, JS; Scher, KS | 1 |
| Feddersen, CR; Fletcher, EV; Goel, A; Koch, AT; Love-Homan, L; Simons, AL; Sobhakumari, A | 1 |
| Austin, MC; Bauman, JE; Chai, X; Hayes, DN; Kurland, BF; Martins, RG; Mendez, E; Parvathaneni, U; Sampath, S; Schmidt, R; Vaezi, A | 1 |
| Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, W; Hurwitz, SJ; Khuri, FR; Kono, SA; Lewis, M; Moore, CE; Moreno-Williams, R; Müller, S; Nannapaneni, S; Owonikoko, TK; Ramalingam, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Yang, CS; Zhao, Y | 1 |
| Andrews, GA; Byers, LA; Fooshee, DR; Frederick, MJ; Galer, C; Hah, JH; Heymach, J; Jasser, SA; Kim, E; Milas, ZL; Myers, JN; Papadimitrakopoulou, V; Pickering, CR; Sano, D; William, WN; Zhao, M | 1 |
| Abraham, I; Bustin, F; De Vos, L; Galdermans, D; Lechat, I; Van Meerbeeck, J | 1 |
| Koyama, N; Uchida, Y | 1 |
| Eicheler, W; Holler, M; Meier, F; Minjgee, M; Rodemann, HP; Saki, M; Toulany, M | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Wirth, LJ | 1 |
| Bogatyreva, L; Braun, JA; Faller, G; Fichter, CD; Geddert, H; Gudernatsch, V; Hauschke, D; Klimstra, D; Lassmann, S; Schöpflin, A; Tang, L; Timme, S; Werner, M | 1 |
| Abdi, E; Button, P; Clarke, S; Clingan, P; Do, H; Dobrovic, A; Gregory, D; Michael, M; Nott, L; Solomon, B; White, SC; Zimet, A | 1 |
| Bansal, N; Center, B; Fetrow, JS; Furdui, CM; Kuremsky, JG; Marrs, GS; Mims, J; Olex, AL; Porosnicu, M; Qian, J; Tsang, AW; Wani, R; Yin, L; Zhao, W | 1 |
| Argiris, A; Bauman, JE; Chiosea, S; Conrads, TP; Denq, W; Ferris, RL; Flint, MS; Gooding, WE; Grandis, JR; Gross, ND; Hood, BL; Johnson, JT; Kim, S; Nikiforova, MN; Siegfried, JM; Sun, M; Thomas, SM; Wang, L; Wirth, L | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Altiok, S; Doshi, P; Fulp, W; Haura, EB; Sasser, K; Smith, MA; Song, L | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M; Topolcan, O | 1 |
| Carroll, WR; Chung, TK; Clemons, L; Desmond, R; Nabell, L; Rosenthal, EL | 1 |
| Jiao, SC; Peng, L; Song, ZG | 1 |
| Atagi, S; Fukuoka, M; Goto, K; Harada, R; Hida, T; Hosomi, Y; Kato, T; Maemondo, M; Nagase, S; Nakagawa, K; Nishio, M; Okamoto, I; Seto, T; Tajima, K; Yamamoto, N; Yamanaka, T | 1 |
| Corsten, M; Dayekh, K; Dimitroulakos, J; Johnson-Obaseki, S; Sekhon, HS; Villeneuve, PJ; Weberpals, JI | 1 |
| Chen, Z; Chen, ZG; Hu, Z; Jiang, N; Kim, S; Müller, S; Qian, G; Saba, NF; Shin, DM; Wang, D; Xu, J; Zhang, H | 1 |
| Clause, AL; Pieters, T; Vanderheyde, K | 1 |
| Aoki, N; Celis, E; Harabuchi, Y; Kimura, S; Kobayashi, H; Kumai, T; Oikawa, K | 1 |
| Aichler, M; Borgmann, DM; Feuchtinger, A; Hauck, SM; Huber, K; Keller, U; Li, Z; Schwaiger, M; Walch, A; Zitzelsberger, H | 1 |
| Becker, A; Heideman, DA; Kuiper, JL; Ronden, MI; Smit, EF; Thunnissen, E; van Hengel, P; Ylstra, B | 1 |
| Espinosa-Cotton, M; Koch, AT; Love-Homan, L; Simons, AL; Stanam, A | 1 |
| Espinosa-Cotton, M; Joseph, TS; Love-Homan, L; Simons, AL; Stanam, A | 1 |
| Hatanaka, Y; Kagawa, S; Kinugasa, H; Komatsu, Y; Kubota, Y; Maehara, O; Marukawa, K; Nakagawa, H; Natsuizaka, M; Ohashi, S; Ohnishi, S; Sakamoto, N; Sato, F; Shimizu, Y; Suda, G; Terashita, K; Whelan, KA | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Einarson, MB; Golemis, EA; Jaffe, EK; Lawrence, SH; Liu, H; Nikonova, AS; Pecherskaya, A; Ramirez, UD; Robinson, MK; Serebriiskii, IG; Zhou, Y | 1 |
| Blumenschein, GR; Canales, JR; Ginsberg, LE; Heymach, JV; Kies, MS; Lee, JJ; Lin, H; Lu, C; Massarelli, E; Papadimitrakopoulou, V; Tran, HT; Williams, MD | 1 |
| Chasapi, V; Soura, E; Stratigos, AJ | 1 |
| Baay, M; Boeckx, C; De Pauw, I; Lardon, F; Peeters, M; Van den Bossche, J; Wouters, A | 1 |
| Amler, LC; Baselga, J; Blumenschein, GR; Bohórquez, SS; Calles, A; Cervantes, A; Dienstmann, R; Hidalgo, M; Jimeno, A; Juric, D; Kapp, AV; Leddy, C; Littman, C; Messersmith, W; Penuel, E; Pirzkall, A; Roda, D; Shames, DS; Tabernero, J; Wang, X | 1 |
| Bothwell, KD; Hershberger, PA; Johnson, CS; Kuriakose, MA; Merzianu, M; Seshadri, M; Shaurova, T; Suresh, A | 1 |
| Bauman, JE; Carter, SL; Chiosea, S; Close, D; Du, Y; Duvvuri, U; Egloff, AM; Garraway, LA; Getz, G; Gilbert, BR; Goetz, EM; Golub, TR; Grandis, JR; Johnson, JT; Johnston, PA; Li, H; Lui, VW; McKenna, A; Mills, GB; Pendleton, KP; Sougnez, C; Stransky, N; Van Allen, EM; Wagle, N; Wang, L; Zeng, Y; Zhang, F | 1 |
| Bettini, A; Broggini, M; Copreni, E; Farina, G; Ganzinelli, M; Garassino, MC; Labianca, R; Lauricella, C; Longo, F; Marabese, M; Marsoni, S; Martelli, O; Moscetti, L; Rulli, E; Torri, V; Veronese, S | 1 |
| De Maria, R; Duranti, E; Eramo, A; Fecchi, K; Gallo, E; Milella, M; Mottolese, M; Pilozzi, E; Policicchio, E; Salvati, V; Sette, G; Tartaglia, M; Visca, P | 1 |
| Dikomey, E; Gleißner, L; Hoffer, K; Kriegs, M; Kwiatkowski, M; Myllynen, L; Petersen, C; Riepen, B; Rothkamm, K; Schlüter, H; Wurlitzer, M | 1 |
| Almeida, DR; Boldt, HC; Chin, EK; Hornick, AL; Kirkpatrick, CA | 1 |
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
| Huang, K; Liu, D | 1 |
| Fu, P; Gibson, M; Lavertu, P; Machtay, M; Rezaee, R; Savvides, P; Sharma, N; Wasman, J; Woods, C; Yao, M; Zender, C | 1 |
| Mehra, R; Zibelman, M | 1 |
| Egloff, AM; Grandis, JR; Li, H; Lui, VW; Pendleton, KP; Wen, W; Wen, Y; Zeng, Y | 1 |
| Cao, W; Chen, Y; Ji, T; Lin, C; Lu, W; Ren, Z; Tang, Y; Wang, L; Wang, X; Yang, R; Zhang, C | 1 |
| Knudson, CM; Kowalski, CE; Love-Homan, L; Orcutt, KP; Parsons, AD; Simons, AL; Sobhakumari, A | 1 |
| Binder, M; Braig, F; Dikomey, E; Grénman, R; Hoffer, K; Kasten-Pisula, U; Kriegs, M; Myllynen, L; Petersen, C; Rieckmann, T; Riepen, B; Rothkamm, K; Struve, N | 1 |
| Ambrosetti, D; Benhamou, Y; Brolih, S; Chamorey, E; Lo Nigro, C; Merlano, M; Monteverde, M; Pagès, G; Picco, V; Raybaud, H; Sudaka, A | 1 |
| Ahn, PH; Anne, PR; Axelrod, RS; Cognetti, D; Dicker, AP; Keane, WM; Machtay, M; Wuthrick, E | 1 |
| Audigier-Valette, C; Blanchon, F; Bonnetain, F; Girard, N; Lamour, C; Molinier, O; Monnet, I; Souquet, PJ; Taguieva-Pioger, N; Vergnenègre, A; Wislez, M | 1 |
| Ahn, MJ; Arpornwirat, W; Bazhenova, L; Chen, J; Chiappori, AA; Chow, LQ; de Lima, LG; Dechaphunkul, A; Eaton, K; Gadgeel, SM; Juergens, RA; Leighl, NB; Medley, S; Poondru, S; Rizvi, NA; Rudin, CM; Singh, M; Steinberg, J; Sunpaweravong, P | 1 |
| Gibson-Corley, KN; Ihejirika, N; Love-Homan, L; Simons, AL; Stanam, A | 1 |
| Berghmans, T; Biesma, B; Chittazhathu Kurian Kuruvilla, Y; Ciardiello, F; Coate, L; Cobo Dols, M; Collado Martin, R; Cuffe, S; Curioni-Fontecedro, A; Dafni, U; de Hosson, S; Garde Noguera, J; Gasca-Ruchti, A; Gautschi, O; Gregorc, V; Groen, HJM; Horgan, A; Insa, A; Juan Vidal, Ó; Kassapian, M; Láng, I; López Martín, A; Mark, MT; Massutí, B; Meldgaard, P; Novello, S; Palmero Sanchez, R; Peralta, S; Peters, S; Pieterman, R; Ponce Aix, S; Rauch, D; Smit, EF; Stahel, RA; Summers, Y; Torri, V; Tsourti, Z; van den Berg, PM; van Heemst, R; van Henten, AMJ; Villa Guzmán, JC; Zielinski, CC | 1 |
| Bass, AJ; Chen, T; Diehl, JA; Liu, JB; Nagaraja, A; Pectasides, E; Rustgi, AK; Sanchez-Vega, F; Sicinska, E; Stachler, M; Wong, G; Wong, KK; Wu, Z; Xu, X; Zhang, H; Zhou, J | 1 |
| Chen, Y; Ge, F; Jia, R; Jin, Y; Lin, L; Liu, J; Liu, R; Wang, Y; Xu, J; Zhao, C | 1 |
| Amin, AR; Anisuzzaman, AS; Chen, Z; Chen, ZG; Haque, A; Rahman, MA; Shin, DM; Wang, D; Zhang, C | 1 |
| Chen, Z'; Khuri, FR; Lee, JE; Shin, DM; Shin, HJ; Tighiouart, M; Yang, CS; Zhang, H; Zhang, X | 1 |
| Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H | 1 |
| Camisão, C; do Carmo, CC; Erlich, F; Ferreira, CG; Fontão, K; Herchenhorn, D; Lima, R; Martins, RG; Moralez, GM; Nogueira-Rodrigues, A; Small, IA; Viegas, C | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Fukuoka, M; Hida, T; Katakami, N; Kawahara, M; Kubota, K; Matsui, K; Nakagawa, K; Nishiwaki, Y; Noda, K; Saijo, N; Takeda, K; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Bodenstein, H; Digel, W; Franke, A; Guschall, WR; Gütz, S; Heigener, D; Laack, E; Reck, M; Schmidtgen, C; Schneider, CP; Schott-von-Römer, K | 1 |
| Choi, W; Haddad, Y; McConkey, DJ | 1 |
| Akerley, W; Arbogast, K; Bentz, JS; Boucher, KM; Walters, T | 1 |
| Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL | 1 |
| Blair, E; Clark, JI; Cohen, EE; Dancey, JE; Davis, DW; Dekker, A; Karrison, TG; Kozloff, MF; Liu, W; Nattam, S; Pierce, C; Seiwert, TY; Stenson, K; Vokes, EE; Wong, SJ; Yan, DH | 1 |
| Brizel, DM | 1 |
| Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC | 1 |
| Chen, ZG; Huang, DH; Khuri, FR; Peng, XH; Shin, DM; Su, L; Zhang, H | 1 |
| Amin, AR; Chen, ZG; Khuri, FR; Shin, DM | 1 |
| Benlyazid, A; Chatelut, E; Delord, JP; Hennebelle, I; Lefebvre, JL; Malard, L; Rochaix, P; Sarini, J; Thomas, F; White-Koning, M | 1 |
| Lee, YC; Mannel, R; Schilder, RJ; Sill, MW | 1 |
| Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R | 1 |
| Ahsan, A; Beer, DG; Hasan, MR; Kausar, T; Lin, L; Ralhan, R | 1 |
| Cai, Q; Freilino, ML; Grandis, JR; Hahm, ER; Johnson, DE; Joyce, SC; Leeman-Neill, RJ; Li, C; Neill, DB; Panahandeh, MC; Seethala, RR; Sen, M; Singh, SV; Thomas, SM; Wheeler, SE | 1 |
| Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Beckett, LA; Burich, RA; Davies, AM; Gandara, DR; Holland, WS; Lara, PN; Li, Y; Mack, PC; Sangha, R; Solis, LJ | 1 |
| Bessho, A; Harita, S; Hayashi, H; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Umemura, S; Yoshioka, H | 1 |
| Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM | 1 |
| Hammersley, JR; Kanjwal, S; Taj, A | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G | 1 |
| Domínguez-Fernández, I; Eguren, C; García-Díez, A; Santiago-Sánchez-Mateos, DI | 1 |
| Burtness, B; Chen, C; Cohen, R; Feigenberg, SJ; Jimeno, A; Kane, M; Lango, M; Mehra, R; Nicolaou, N; Raben, D; Ridge, J; Rusthoven, KE; Song, JI; Swing, R | 1 |
| Fujita, S; Fukudo, M; Ikemi, Y; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Eguchi, K; Fukuoka, M; Horai, T; Ichinose, Y; Masuda, N; Mitsudomi, T; Mori, K; Nukiwa, T; Saijo, N; Segawa, Y; Takahashi, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Deng, X; Hu, W; Li, G; Wang, J; Wu, S; Xie, C; Zhang, P; Zhang, X | 1 |
| Arbiser, JL; Bhola, NE; Cai, Q; Grandis, JR; Joyce, SC; Leeman-Neill, RJ; Neill, DB; Thomas, SM | 1 |
| Araújo, CM; Bezerra, M; Dias, FL; Federico, MH; Ferreira, CG; Fontão, K; Herchenhorn, D; Knust, RE; Martins, RG; Small, I; Viegas, CM | 1 |
| Anthoney, A; Blatter, J; Dean, E; Hanauske, AR; Kletzl, H; Klingelschmitt, G; Melezinek, I; Ranson, M; Reck, M; Twelves, C | 1 |
| Agrawal, A; Aimiumu, J; Chan, KK; Chen, P; Cheng, H; Dancey, J; Grever, MR; Kraut, EH; Lang, J; Rhoades, C; Young, DC; Zhang, Y | 1 |
| Brückl, WM; Ficker, JH; Wiest, GH | 1 |
| Babineaux, S; Klein, R; Lawson, A; Liepa, AM; Muehlenbein, C; Schwartzberg, L; Wielage, R | 1 |
| English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A | 1 |
| Allan, S; Baliko, Z; Gridelli, C; Heigener, D; Krzakowski, M; Reck, M; Rischin, D; van Zandwijk, N | 1 |
| Au, JS; Mok, T; Park, K; Perng, RP; Wu, YL; Zhang, L; Zhou, C | 1 |
| Ferris, RL; Ferrone, S; Grandis, JR; Sharafinski, ME | 1 |
| Chen, YM; Chou, KT; Fan, WC; Hsia, TC; Huang, MS; Huang, SF; Lai, CL; Lee, YC; Perng, RP; Tien, YJ; Tsai, CM; Wu, CH; Yu, CJ | 1 |
| Dong, N; Guo, Y; Luan, HL; Sun, BC; Sun, LN; Wang, M; Zang, FL; Zhan, ZL | 1 |
| Azzoli, CG; Brevet, M; Johnson, ML; Ladanyi, M | 1 |
| Chattopadhyay, S; Cohen, MH; Johnson, JR; Justice, R; Pazdur, R; Sridhara, R; Tang, S | 1 |
| Bednash, JS; Freilino, ML; Gooding, WE; Grandis, JR; Joyce, SC; Leeman-Neill, RJ; Lingen, MW; Neill, DB; Panahandeh, MC; Seethala, RR; Singh, SV; Thomas, SM | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Anthoine, G; Berghmans, T; CsToth, I; Mascaux, C; Meert, AP; Paesmans, M; Sculier, JP | 1 |
| Boyd, J; Capanu, M; Ilson, DH; Kelsen, D; Klimstra, D; Levine, DA; Miron, B; Schwartz, G; Shah, M | 1 |
| Goswami, P; Kalen, AL; Miller, FJ; Orcutt, KP; Parsons, AD; Scarbrough, PM; Sibenaller, ZA; Simons, AL; Sobhakumari, A; Spitz, DR; Wilke, WW; Zhu, Y | 1 |
| Chatelut, E; Civade, E; Delord, JP; Geoerger, B; Hennebelle, I; Le Deley, MC; Thomas, F; Vassal, G; White-Koning, M | 1 |
| Baumann, M; Bütof, R; Deuse, Y; Eicheler, W; Grenman, R; Gurtner, K; Krause, M; Oertel, R; Schaal, K; Thames, H; Yaromina, A | 1 |
| Cranmer, L; Curiel-Lewandrowski, C; Engelhardt, C; Warneke, J | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| Arias de la Vega, F; Arrazubi, V; Calvo, FA; Contreras, J; de la Torre, A; de Las Heras, M; García-Saenz, JA; Herruzo, I; Prieto, I; Romero, J | 1 |
| Chu, QS; de Jonge, MJ; Hamilton, M; Iwata, K; McCarthy, S; Mita, AC; Mita, MM; Papadopoulos, K; Ricart, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Verweij, J; Wacker, B; Witt, K; Wood, L | 1 |
| Baumeister, P; Harréus, U; Heinrich, K; Märte, M; Reiter, M; Schwenk-Zieger, S | 1 |
| Chen, ZG; Huang, D; Shin, DM; Su, L; Wang, D; Zhang, H | 1 |
| Bacha, OM; Lalancette, M; Levesque, E; Renaud, MC | 1 |
| Benz, G; Brutsche, M; Früh, M; Putora, PM; Rodriguez, R | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Chen, YM; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Agulnik, M | 1 |
| Bienvenu, S; Chaudhry, MA; Forastiere, A; Gilbert, J; Gillison, M; Higgins, MJ; Rudek, MA; Tsottles, N; Wahl, R; Zhao, M | 1 |
| Agatsuma, T; Eda, S; Hachiya, T; Kobayashi, T; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Ohura, N; Tsushima, K; Yasuo, M | 1 |
| Böker, B; Grohé, C; Lüders, H | 1 |
| Chang, GC; Chen, HY; Chen, KC; Hsu, KH; Tseng, JS; Yang, TY | 1 |
| Chang, X; Chatterjee, A; Horii, A; Kobayashi, T; Koch, WM; Kusuke, D; Levenson, VV; Liggett, TE; Melnikov, AA; Monitto, CL; Ogawa, T; Shiga, K; Sidransky, D | 1 |
| Clayburgh, DR; Gross, ND; Koide, J; Proby, C; Wong, MH | 1 |
| Dittmann, K; Huber, SM; Mayer, C; Misovic, M; Rodemann, HP | 1 |
| Ariansen, S; Berg, T; Bremnes, R; Brustugun, OT; Dai, HY; Dønnem, T; Fjellbirkeland, L; Grønberg, BH; Helgeland, L; Helland, Å; Jebsen, P; Kleinberg, L; Mangseth, K; Scott, H; Wahl, SG | 1 |
| Abemayor, E; Dennis, M; Dohadwala, M; Dubinett, SM; Elashoff, DA; Lin, Y; Luo, J; Sharma, S; St John, MA; Wang, G | 1 |
| Ando, M; Fukuoka, M; Johkoh, T; Kudoh, S; Nakagawa, K; Ohe, Y; Seki, A; Takemoto, S; Yamazaki, N | 1 |
| Gasol-Cudós, A; Llombart-Cussac, A; Márquez-Medina, D; Salud-Salvia, A; Samamé Pérez-Vargas, JC; Taberner-Bonastre, MT | 1 |
| Argiris, A; Ferris, RL; Freilino, ML; Gooding, WE; Grandis, JR; Gross, N; Moskowitz, HS; Thomas, SM | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Borger, DR; Brard, L; Dizon, DS; Growdon, WB; Horowitz, NS; Krasner, CN; Lee, J; Liu, JF; Matulonis, UA; Olawaiye, AB | 1 |
| Grandis, JR; Quesnelle, KM; Ratay, MK; Wheeler, SE | 1 |
| Benlyazid, A; Delmar, P; Delord, JP; Hennebelle, I; McLoughlin, P; Rochaix, P; Sarini, J; Thomas, F; Vergez, S | 1 |
| Gooding, WE; Grandis, JR; Johnson, DE; Joyce, S; Li, C; Maxwell, J; Panahandeh, M; Sen, M; Thomas, SM; Wang, L | 1 |
| Chen, B; Hui, Z; Liang, J; Lv, J; Wang, J; Wang, L; Wang, X; Zhai, Y; Zhu, H; Zou, S | 1 |
| Chang, J; Cho, BC; Hong, S; Jung, M; Kang, YA; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Rha, SY | 1 |
| An, TT; Bai, H; Duan, JC; Wang, J; Wang, SH; Wang, YY; Wang, ZJ; Wu, MN; Yang, L; Zhao, J; Zhuo, ML | 1 |
| Kris, MG; Ladanyi, M; Moreira, AL; Paik, PK; Rekhtman, N; Sima, CS; Varghese, AM | 1 |
| Ahsan, A; Bradford, CR; Chepeha, DB; D'Silva, N; Eisbruch, A; Helman, JI; Lawrence, TS; Nyati, MK; Ramanand, SG; Tsien, CI; Wolf, GT; Worden, FP | 1 |
| Chen, X; Duvvuri, U; Fung, C; Grandis, JR | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Commandeur, S; de Gruijl, FR; El Ghalbzouri, A; van Drongelen, V | 1 |
| Antoine, M; Blons, H; Buisine, MP; Cadranel, J; Chetaille, B; Chouaid, C; Coudert, B; Daniel, C; Danton, G; De Fraipont, F; Faller, M; Foucher, P; Lacroix, L; Longchampt, E; Mauguen, A; Michiels, S; Morin, F; Pignon, JP; Poulot, V; Quoix, E; Solassol, J; Urban, T; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Chen, YM; Chiang, CL; Chiu, CH; Chou, TY; Lai, SL; Lee, YC; Shih, JF; Tsai, CM | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Carbone, DP; Ding, K; Grigorieva, J; Roder, H; Roder, J; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M; Ricar, J | 1 |
| Fletcher, EV; Knudson, CM; Love-Homan, L; Martin, SM; Parsons, AD; Simons, AL; Sobhakumari, A; Spitz, DR | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Amler, LC; Armstrong, EA; Harari, PM; Huang, S; Li, C; Peet, CR; Saker, J; Sliwkowski, MX | 1 |
| Carroll, WR; Clemons, L; Deep, NL; Desmond, R; Heath, CH; Magnuson, JS; Nabell, L; Rosenthal, EL; Spencer, S | 1 |
| Barr, S; Cassell, A; Freilino, ML; Grandis, JR; Lee, J; Panahandeh, MC; Thomas, SM; Wang, L | 1 |
| El-Sawy, T; Esmaeli, B; Glisson, BS; Kies, MS; Lippman, S; Myers, JN; Sabichi, AL; William, WN | 1 |
| Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Korogi, Y; Kunimasa, K; Nishiyama, A; Notohara, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Baik, CS; Chow, LQ; Eaton, KD; Pritchard, CC | 1 |
| Chen, Y; Sun, C; Zhang, X | 1 |
| Endo, H; Higashiyama, M; Imamura, F; Inoue, M; Kondo, J; Kumagai, T; Nishizawa, Y; Okami, J; Okuyama, H; Takehara, T; Uchida, J | 1 |
| Giuliani, J; Marzola, M | 1 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Arias-Pulido, H; Bauman, JE; Bishop, J; Chung, CH; Fekrazad, MH; Fertig, E; Howard, J; Jones, DV; Lee, SJ; Olson, GT; Ozawa, H; Spafford, MJ; Wang, H | 1 |
| Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Bryant, JA; Charles, AC; Cloughesy, TF; Finn, RS; Slamon, DJ | 1 |
| Fenyo, D; Gibson, N; Griffin, G; Haley, JD; Hunt, T; Iwata, K; Petti, F; Settinari, T; Thelemann, A | 1 |
| Armstrong, E; Chinnaiyan, AM; Chinnaiyan, P; Harari, PM; Huang, S; Tomlins, SA; Vallabhaneni, G; Varambally, S | 1 |
| Chen, YF; Cohen, MH; Johnson, JR; Pazdur, R; Sridhara, R | 1 |
| Höpfner, M; Huether, A; Maaser, K; Scherübl, H; Sutter, AP | 1 |
| Bonner, JA; Clemons, LK; Dobelbower, MC; Posey, J; Raisch, KP; Russo, SM; Seay, LL; Suter, S | 1 |
| Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N | 1 |
| Khuri, FR; Saba, NF; Shin, DM | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N | 1 |
| Achille, M; Gallegos-Ruiz, M; Giaccone, G; Soria, JC | 1 |
| Baillargeon, GM; Calvo, E; Chin, SF; Hidalgo, M; Irish, J; Kreisberg, JI; Malik, SN; Rowinsky, EK; Santabarbara, P; Siu, LL | 1 |
| Chandra, NR; Efferth, T; Gebhart, E; Konkimalla, VB; Suhas, VL | 1 |
| Chan, A; Chen, R; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P; Wheelhouse, J; Zhang, X | 1 |
| Burtness, BA; Forastiere, AA | 1 |
| Chen, EX; Chin, SF; Dancey, J; Eisenhauer, EA; Francis, P; Harvey, L; Klein, M; Pond, GR; Siu, LL; Soulieres, D; Winquist, E; Zhang, W | 1 |
| Agulnik, M; Chen, EX; Chen, H; Chen, S; da Cunha Santos, G; Dancey, J; Dos Reis, PP; Hedley, D; Ho, J; Kamel-Reid, S; Marrano, P; Nicklee, T; Pond, GR; Shyr, Y; Siu, LL; Soulieres, D; Squire, JA; Tsao, MS; Winquist, E | 1 |
| Horowitz, N; Krasner, C; Lee, LM; Olawaiye, A | 1 |
| Aguilar, RJ; Bartholomeusz, C; Felix, E; Hortobagyi, GN; Johansen, MJ; Krishnamurthy, S; Kurisu, K; Mills, GB; Ueno, NT; Yamasaki, F; Zhang, D | 1 |
| Gyergyay, F | 1 |
| Hermanns, JF; Piérard, GE; Quatresooz, P | 1 |
| Brun, L; Colin, G; Copin, MC; Lafitte, JJ; Makris, D; Marquette, CH; Scherpereel, A | 1 |
| Allal, BC; Benlyazid, A; Chatelut, E; Courbon, F; Delord, JP; Lefebvre, JL; Rives, M; Rochaix, P; Sarini, J; Thomas, F | 1 |
| Alvarez-Hernandez, D; Arcidiacono, MV; Cannata-Andia, J; Dusso, AS; Gonzalez-Suarez, I; Lu, Y; Sato, T; Slatopolsky, E; Tokumoto, M; Tominaga, Y; Yang, J | 1 |
| Atkinson, DM; Carlson, BL; Clarke, MJ; Jacobson, MS; Kemp, BJ; Lowe, VJ; Mladek, AC; Sarkaria, JN; Trump, DP | 1 |
| Boehm, AL; Freilino, M; Gooding, WE; Grandis, JR; Johnson, DE; Seethala, R; Sen, M; Wang, S; Wong, SM | 1 |
| Glisson, BS; Johnson, FM; Saigal, B | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
19 review(s) available for erlotinib hydrochloride and Carcinoma, Epidermoid
| Article | Year |
|---|---|
T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.
Topics: Adenocarcinoma of Lung; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Vulvar Neoplasms | 2021 |
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors | 2018 |
The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Panitumumab; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin Neoplasms | 2014 |
Pharmacologic treatment options for advanced epithelial skin cancer.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Pyridines; Quality of Life; Quinazolines; Skin Neoplasms; Treatment Outcome | 2015 |
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines | 2010 |
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2012 |
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
[Targeting of epidermal growth factor receptor and applications in ORL cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines | 2003 |
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
Diagnosis and therapy of oral squamous cell carcinoma.
Topics: Age Factors; Alcohol Drinking; Antineoplastic Agents; Aporphines; Azo Compounds; Berberine; Carcinoma, Squamous Cell; Chromosome Aberrations; Crystallography, X-Ray; Databases, Factual; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Mouth Neoplasms; Neoplasm Proteins; Nucleic Acid Hybridization; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Stilbenes; Structure-Activity Relationship | 2007 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
76 trial(s) available for erlotinib hydrochloride and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Predictive Value of Tests; Protein Kinase Inhibitors; Proteomics; Survival Rate | 2019 |
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Treatment Outcome | 2017 |
Evaluation of the VeriStrat
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Hematologic Tests; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis; Treatment Outcome | 2017 |
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Reported Outcome Measures; Platinum Compounds; Quality of Life; Survival Analysis | 2018 |
Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Skin Neoplasms | 2018 |
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Topics: Afatinib; Aged; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Movement; Cell Proliferation; Cyclooxygenase Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Prognosis; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Tumor Cells, Cultured | 2013 |
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Male; Pain; Quinazolines; Remission Induction; Treatment Outcome | 2013 |
Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Tandem Mass Spectrometry | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Prospective Studies; Quinazolines; Thoracic Duct | 2013 |
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Injections, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Quinazolines | 2013 |
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Topics: Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; DNA-Binding Proteins; Endonucleases; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Prospective Studies; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Disease Progression; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pyrazoles; Quinazolines; Sulfonamides | 2014 |
Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2014 |
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2015 |
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sulindac; Tissue Array Analysis | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate | 2014 |
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunoglobulin G; Male; Middle Aged; Panitumumab; Receptor, ErbB-3; Squamous Cell Carcinoma of Head and Neck | 2015 |
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Proto-Oncogene Proteins p21(ras); Survival Rate; Taxoids | 2015 |
Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiotherapy, Intensity-Modulated; Taxoids | 2016 |
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate | 2018 |
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate | 2017 |
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic On
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Prognosis; Survival Rate; Taxoids | 2017 |
A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Paclitaxel; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Quinazolines; Radiation Oncology; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2008 |
Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Germany; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2008 |
A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2009 |
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult | 2009 |
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retreatment; Treatment Outcome | 2010 |
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Feasibility Studies; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Thrombocytopenia | 2010 |
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Drug Administration Schedule; Drug Eruptions; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Quinazolines; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 2010 |
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome | 2010 |
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Chromatography, Liquid; Docetaxel; Dose-Response Relationship, Drug; Enzyme Induction; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Tandem Mass Spectrometry; Taxoids | 2011 |
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Mutation; Quinazolines; Retreatment | 2011 |
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Squamous Cell; Child; Child, Preschool; Cytochrome P-450 CYP3A; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Young Adult | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2012 |
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2012 |
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Interleukin-6; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Placebos; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sulindac; Transforming Growth Factor alpha | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms | 2012 |
Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagitis; Exanthema; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Survival Rate | 2013 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate | 2012 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Skin Neoplasms; Stomatitis | 2013 |
[Therapeutic effect of erlotinib in elderly patients with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2012 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Platinum; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6 Kinases; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2013 |
FDA drug approval summary: erlotinib (Tarceva) tablets.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines | 2007 |
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Topics: Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Skin | 2007 |
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p21; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Hybridization; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines | 2007 |
153 other study(ies) available for erlotinib hydrochloride and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life.
Topics: Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Evidence-Based Nursing; Humans; Lung; Oxonic Acid; Potassium; Pyridines; Quality of Life; Retrospective Studies; Tegafur | 2021 |
Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells.
Topics: Antineoplastic Agents; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung; Lung Neoplasms; Pyrimidine Nucleosides; RNA, Small Interfering; Tamoxifen; Thymidine Phosphorylase | 2022 |
Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mice; Mouth Neoplasms; Pyruvate Kinase; Quercetin; Squamous Cell Carcinoma of Head and Neck | 2023 |
Localized delivery of Erlotinib using liposomal gel formulations for the treatment of oral squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Liposomes; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck | 2023 |
Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways.
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Serum | 2023 |
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Regulatory role of transcription factor HBP1 in anticancer efficacy of EGFR inhibitor erlotinib in HNSCC.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; High Mobility Group Proteins; Humans; Repressor Proteins; Squamous Cell Carcinoma of Head and Neck; Transcription Factors | 2020 |
Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Humans; Precision Medicine | 2020 |
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Line, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Small Interfering; Signal Transduction; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics.
Topics: Amino Acids; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Isotope Labeling; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Tyrosine | 2021 |
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2017 |
Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Topics: Animals; Carcinoma, Squamous Cell; Cell Differentiation; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
Topics: Administration, Oral; Animals; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterografts; Humans; Immunotherapy; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Permeability; Tumor Microenvironment | 2017 |
A rare complication of metastatic lung disease treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Etoposide; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Pericardium; Tomography, X-Ray Computed; Tongue Neoplasms | 2017 |
Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Valine; Xenograft Model Antitumor Assays | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer.
Topics: Amiodarone; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Paralysis; Radiotherapy; Withholding Treatment | 2018 |
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Inflammation Mediators; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proteomics; Survival Rate | 2018 |
Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; China; Clinical Decision-Making; Cost-Benefit Analysis; Decision Support Techniques; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Economic; Progression-Free Survival; Quality-Adjusted Life Years | 2018 |
In Search of an Oncogene Driver for Squamous Lung Cancer.
Topics: Afatinib; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation | 2018 |
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2018 |
Is EGFR really a therapeutic target in head and neck cancers?
Topics: Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Radiotherapy, Adjuvant | 2019 |
The 4717C > G polymorphism in periplakin modulates sensitivity to EGFR inhibitors.
Topics: Biomarkers, Pharmacological; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Mouth Neoplasms; Phosphorylation; Plakins; Polymorphism, Single Nucleotide; Quinazolines; Signal Transduction | 2019 |
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Signal Transduction; Tumor Cells, Cultured | 2013 |
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Recurrent respiratory papillomatosis with lung involvement and malignant transformation.
Topics: Bronchial Neoplasms; Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Contrast Media; Disease Progression; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Erlotinib in the treatment of advanced squamous cell NSCLC.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
Topics: Autophagy; Carcinoma, Squamous Cell; Cytoprotection; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; HEK293 Cells; Humans; NADPH Oxidase 4; NADPH Oxidases; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2013 |
EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas.
Topics: Antibodies, Monoclonal, Humanized; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Lineage; Cetuximab; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mesoderm; Neoplasm Invasiveness; Quinazolines; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipient.
Topics: Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Erlotinib Hydrochloride; Humans; Kidney Transplantation; Lung Neoplasms; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Thoracic Surgery, Video-Assisted | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2013 |
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cytokines; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inflammation; Lapatinib; NADPH Oxidase 4; NADPH Oxidases; Oligonucleotide Array Sequence Analysis; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2013 |
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Mice; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sensitivity and Specificity; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transfection | 2014 |
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Furans; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Quinazolines; ras Proteins; Signal Transduction | 2014 |
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Pyrazoles; Quinazolines; Sulfonamides | 2014 |
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured | 2014 |
Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phenotype; Phosphorylation; Quinazolines; Radiation Tolerance; Radiation, Ionizing; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2014 |
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Female; Fibroblasts; Humans; Interleukin-6; Lung Neoplasms; Mice; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Serine; STAT3 Transcription Factor; Tyrosine | 2014 |
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Monensin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2014 |
Human papillomavirus 16 oncoprotein regulates the translocation of β-catenin via the activation of epidermal growth factor receptor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Oncogene Proteins, Viral; Oropharyngeal Neoplasms; Papillomavirus E7 Proteins; Predictive Value of Tests; Prognosis; Quinazolines; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Translocation, Genetic | 2015 |
[Safety of reintroduction of erlotinib at low doses following hand-foot syndrome induced by erlotinib treatment for a Pancoast-Tobias tumour].
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Pancoast Syndrome; Protein Kinase Inhibitors; Quinazolines; Retreatment | 2014 |
Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor.
Topics: Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Transforming Growth Factor beta | 2014 |
Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Immunohistochemistry; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2014 |
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Knockout; Mice, Nude; Myeloid Differentiation Factor 88; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Cells, Cultured | 2015 |
Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Interleukin-6; Up-Regulation | 2015 |
EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Homeodomain Proteins; Humans; Neoplastic Stem Cells; Spheroids, Cellular; Transcription Factors; Tumor Burden; Tumor Cells, Cultured; Zinc Finger E-box-Binding Homeobox 1 | 2015 |
Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; GRB2 Adaptor Protein; Head and Neck Neoplasms; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Molecular Dynamics Simulation; Phosphorylation; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Transport; Signal Transduction | 2015 |
The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
Topics: Carcinoma, Squamous Cell; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2015 |
Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.
Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Carcinogens; Carcinoma, Squamous Cell; Disease Progression; Down-Regulation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, SCID; Mouth Neoplasms; Neoplasm Transplantation; Quinolones | 2015 |
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; Male; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Phenotype; Phosphorylation; Predictive Value of Tests; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Remission Induction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Tongue Neoplasms; Treatment Outcome | 2015 |
Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2; Signal Transduction; Tyrosine; Xenograft Model Antitumor Assays | 2015 |
Quantitative proteomics unveiled: Regulation of DNA double strand break repair by EGFR involves PARP1.
Topics: Carcinoma, Squamous Cell; DNA; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Head and Neck Neoplasms; Humans; Intracellular Signaling Peptides and Proteins; Phosphorylation; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteomics; RNA Interference; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Tumor Suppressor p53-Binding Protein 1 | 2015 |
Erlotinib-associated bilateral anterior uveitis: resolution with posterior sub-Tenon's triamcinolone without erlotinib cessation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Glucocorticoids; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Staging; Tenon Capsule; Triamcinolone Acetonide; Uveitis, Anterior | 2015 |
Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Hydroxychloroquine; RNA, Small Interfering; Sirolimus; Tongue Neoplasms; Up-Regulation | 2016 |
MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
Topics: Amphiregulin; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Proliferation; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mutation; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Chloroquine; Deoxyglucose; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Female; Glucose; Head and Neck Neoplasms; Humans; Membrane Proteins; Mice; Mice, Nude; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2016 |
Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck; Tumor Suppressor Protein p53 | 2016 |
Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Mouth Neoplasms; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Telomeric Repeat Binding Protein 2; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quality of Life; Retreatment; Treatment Outcome | 2016 |
Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytokines; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Inflammation Mediators; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Mice; Prognosis; Protein Kinase Inhibitors; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Transcriptome; Xenograft Model Antitumor Assays | 2016 |
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Amplification; Humans; Mice; Mitogen-Activated Protein Kinases; Phenotype; Protein Kinase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Morpholines; Proto-Oncogene Proteins c-akt; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Transplantation, Heterologous | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; delta-Crystallins; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Homeodomain Proteins; Humans; Mesoderm; Phenotype; Protein Kinase Inhibitors; Quinazolines; Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2009 |
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured | 2009 |
Targeting the future in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2009 |
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lung Neoplasms; Lysosomes; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quantum Dots; Quinazolines; Signal Transduction | 2009 |
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Catechin; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Transcription Factor RelA; Tumor Suppressor Protein p53 | 2009 |
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines | 2009 |
Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines.
Topics: Antigens, Surface; Antineoplastic Agents; Benzoquinones; Biomarkers, Tumor; Blotting, Western; Calmodulin-Binding Proteins; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Cisplatin; Erlotinib Hydrochloride; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunoprecipitation; Lactams, Macrocyclic; Mass Spectrometry; Membrane Proteins; Protein Binding; Protein Interaction Mapping; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Cisplatin; Commiphora; Drug Synergism; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neoplasm Transplantation; Phytotherapy; Plant Preparations; Pregnenediones; Quinazolines; STAT3 Transcription Factor | 2009 |
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.
Topics: Aged; Biopsy; Brain Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Quinazolines; Tomography, X-Ray Computed | 2011 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
[Erlotinib-induced acneiform rash not affecting previously irradiated skin].
Topics: Acneiform Eruptions; Antineoplastic Agents; Arm; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Humans; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Neck Dissection; Neoplasm Proteins; Organ Specificity; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Skin; Thorax | 2010 |
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Renal Dialysis; Tissue Distribution; Treatment Outcome | 2010 |
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; Drug Synergism; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lignans; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Markov Chains; Neoplasm Staging; Pemetrexed; Placebos; Quinazolines; Remission Induction; Survival Rate; Treatment Outcome | 2010 |
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome | 2010 |
Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2011 |
[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking; Young Adult | 2010 |
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Mutation, Missense; Quinazolines; Sequence Deletion | 2011 |
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.
Topics: 4-Nitroquinoline-1-oxide; Animal Feed; Animals; Carcinogens; Carcinoma, Squamous Cell; Commiphora; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Immunoenzyme Techniques; Mice; Mice, Inbred CBA; Mouth Neoplasms; Plant Extracts; Plant Gums; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2011 |
C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Survival Rate | 2011 |
Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.
Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Growth Processes; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2011 |
Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Logistic Models; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Statistics, Nonparametric; Tumor Microenvironment | 2011 |
Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy.
Topics: Axilla; Biopsy, Needle; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Shoulder; Skin Neoplasms; Treatment Outcome | 2011 |
The impact of EGFR stimulation and inhibition on BPDE induced DNA fragmentation in oral/oropharyngeal mucosa in vitro.
Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Case-Control Studies; Cetuximab; Cisplatin; DNA Damage; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Necrosis Factor-alpha; Up-Regulation; Young Adult | 2011 |
Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Protein Stability; Quinazolines; RNA Interference; RNA Stability; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2011 |
A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Quinazolines; Vulvar Neoplasms | 2011 |
Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Granuloma, Pyogenic; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tracheal Diseases | 2011 |
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2011 |
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis | 2012 |
Retrospective study of erlotinib in patients with advanced squamous lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 1; Podophyllotoxin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |
EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Membrane Potentials; Patch-Clamp Techniques; Phlorhizin; Protein-Tyrosine Kinases; Quinazolines; Radiation Dosage; Sodium-Glucose Transport Proteins; Tumor Cells, Cultured | 2012 |
[Mutation testing for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Polymerase Chain Reaction; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2012 |
Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells.
Topics: beta Catenin; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Chi-Square Distribution; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Phenotype; Quinazolines; Snail Family Transcription Factors; Transcription Factors; Wound Healing | 2012 |
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Survival Rate; Young Adult | 2012 |
Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Papillomavirus Infections; Prevalence; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Spain | 2013 |
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma.
Topics: Basic Helix-Loop-Helix Transcription Factors; Biomarkers; Carcinoma, Squamous Cell; Carrier Proteins; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Keratin-19; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Factors | 2012 |
[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography; Treatment Outcome | 2012 |
Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
Topics: Adolescent; Adult; Carcinoma, Squamous Cell; Cell Culture Techniques; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Young Adult | 2013 |
EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Lung Neoplasms; Mouth Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Sirolimus; Ubiquitin-Activating Enzymes | 2012 |
Epidermal growth factor receptor activation and inhibition in 3D in vitro models of normal skin and human cutaneous squamous cell carcinoma.
Topics: Adult; Carcinoma, Squamous Cell; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines; Skin; Skin Neoplasms | 2012 |
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Factors; Survival Rate | 2012 |
Erlotinib in patients with advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2013 |
Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Auranofin; Buthionine Sulfoximine; Carcinoma, Squamous Cell; Catalase; Cell Line, Tumor; Cell Survival; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Necrosis; Oxidation-Reduction; Oxidative Stress; Peroxiredoxins; Quinazolines; RNA, Small Interfering; Thioredoxin-Disulfide Reductase; Thioredoxins; Xenograft Model Antitumor Assays | 2012 |
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Quinazolines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays | 2012 |
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Male; Orbital Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2013 |
EGFR mutations in squamous cell lung cancer in never-smokers.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Epidural Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Smoking; Thoracic Vertebrae | 2013 |
Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.
Topics: Adenocarcinoma; Animals; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium; Calcium Signaling; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Purinergic; Tumor Cells, Cultured | 2004 |
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Chromatography, Affinity; Chromatography, Liquid; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoblotting; Isotopes; Mass Spectrometry; Models, Biological; Peptide Mapping; Phosphorylation; Phosphotyrosine; Proteins; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; src-Family Kinases | 2005 |
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2006 |
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A | 2006 |
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2007 |
Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Quinazolines; Skin | 2007 |
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Growth Inhibitors; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2007 |
Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Head and Neck Neoplasms; Humans; Polymerase Chain Reaction; Quality of Life; Quinazolines | 2007 |
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.
Topics: Aged; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms | 2007 |
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Chromatography, Liquid; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gene Dosage; Humans; Immunoprecipitation; In Situ Hybridization, Fluorescence; Mass Spectrometry; Molecular Sequence Data; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Transfection; Up-Regulation | 2007 |
[Role of targeted therapy in the treatment of squamous cell head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2007 |
Erlotinib-responsive actinic keratoses.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inflammation; Keratosis; Male; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Skin Neoplasms; Sunlight | 2007 |
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinazolines; Tomography, X-Ray Computed | 2007 |
EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease.
Topics: Animals; Calcitriol; Carcinoma, Squamous Cell; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Disease Models, Animal; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, Reporter; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Renal Insufficiency, Chronic; Transforming Growth Factor alpha | 2008 |
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Dideoxynucleosides; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines | 2008 |
Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2008 |
Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Quinazolines; Taxoids | 2008 |